I have a photograph on my computer — two images, side by side, of the same patient, three years apart. The later photograph was taken when she came back to see me after a period she described as “the most stressful three years of her life.” Divorce, business difficulties, terrible sleep. She was 53.
The difference between the two photographs is not just lines or volume. It is the quality of the skin itself — thinner, more translucent, sitting differently on the bone. There is a fragility to the later image that the earlier one doesn’t have. When I looked at her records, she had stopped her oestrogen therapy eighteen months before the second photograph was taken, for reasons I understood but medically disagreed with.
That is oestrogen loss made visible.
What oestrogen does structurally in the skin
Oestrogen has receptors in skin — this is sometimes surprising to patients, who think of it primarily as a reproductive hormone. In skin, oestrogen receptors are found in keratinocytes, fibroblasts, melanocytes, sebaceous glands, and hair follicles. This distribution tells you something about the breadth of oestrogen’s effects on skin structure.
The primary structural role is collagen maintenance. Oestrogen stimulates fibroblast activity — the cells responsible for collagen and elastin production. It upregulates the expression of collagen type I and III, and suppresses the activity of matrix metalloproteinases, which are the enzymes that degrade collagen. When oestrogen declines, fibroblast activity falls, MMP activity rises, and collagen degradation outpaces synthesis [1].
The quantitative consequences are significant. Research has shown that women lose approximately 2.1% of skin collagen per year in the first five years after menopause — more than double the rate of decline in the premenopausal decade [2]. The skin doesn’t just thin; it loses mechanical strength and structural integrity. The dermis becomes more porous, less able to retain water, and less resistant to the gravitational forces that cause descent and laxity.
In my practice at SW1 Clinic, I can often tell from a consultation when a patient has been through untreated menopause for several years. The skin has a particular quality — dry and slightly crepe-like even on the cheeks, with a thinness that is different from the thinning of UV damage. It responds differently to treatments. It bruises more easily. It recovers more slowly from procedures.
The specific facial changes nobody warns you about
Most of the public conversation about menopause and skin focuses on dryness. Dryness is real — oestrogen maintains glycosaminoglycan synthesis in the dermis, and glycosaminoglycans (including hyaluronic acid) are the primary drivers of dermal hydration. When they decline, skin loses its plumpness and capacity to retain moisture.
But the changes go further than dryness.
The mid-face descends faster in the oestrogen-deficient state. This is partly structural collagen loss, partly the accelerated resorption of facial bone — which is also oestrogen-dependent — and partly the redistribution of facial fat pads that occurs in the hormonal transition. The bony scaffolding of the face literally changes shape. Orbital rim, maxilla, mandible — all undergo measurable resorption in the postmenopausal state [3]. No topical treatment reaches bone.
The periorbital area often shows the changes most acutely. The skin around the eye is already the thinnest on the face; with oestrogen withdrawal, it becomes genuinely fragile. Fine lines appear that have a different quality from UV-induced lines — they are fine, numerous, and appear even at rest. They do not respond well to neurotoxin, because they are not dynamic in origin. They respond to improving skin quality from within — which requires hormonal support as a foundation.
Jaw definition softens. This is partly volume loss from fat pad redistribution, partly the skeletal changes, and partly reduced skin tension. The jowl forms more rapidly in the oestrogen-deficient state than the treatment industry typically acknowledges.
Why Asian women experience this differently
Asian women enter menopause at a median age that is approximately one to two years younger than Western women — though this varies considerably by ethnicity within the Asian category. The experience of menopause itself is also shaped by cultural context in ways that matter clinically.
In Singapore and across East and Southeast Asia, women are significantly less likely to seek hormone therapy than their Western counterparts. This is partly the legacy of the 2002 Women’s Health Initiative study — which generated widespread fear about hormone therapy that was never adequately calibrated to the actual findings — and partly cultural attitudes that equate suffering through natural processes with virtue.
The result is a large population of Asian women navigating menopause without hormonal support, and experiencing the full structural consequences of unchecked oestrogen withdrawal. By the time many of them arrive in my clinic, the changes are established and we are working in a deficient environment.
I discuss hormone therapy openly with my patients and refer appropriately. This is not cosmetic medicine. It is health optimisation that happens to have cosmetic consequences — significant ones.
What topical oestrogen does
Topical oestrogen — which is separate from systemic hormone therapy and applied directly to skin — has genuine evidence for improving skin thickness, collagen content, and dermal hydration. It is available by prescription. Studies have shown that topical oestrogen applied to facial skin improved collagen content and skin elasticity in postmenopausal women within three months [1].
Topical oestrogen is not a substitute for systemic hormone therapy if systemic symptoms are present, but it is an option for women who want to address skin-specific oestrogen withdrawal effects with a targeted approach. This conversation should happen with a physician, not a pharmacist.
What you can actually do
If you are in perimenopause or postmenopause and your skin has changed significantly, have a hormone assessment. A simple oestradiol level combined with FSH provides the basic picture. Then have a proper conversation about management options with a physician who is knowledgeable about both systemic hormone therapy and its evidence base.
Topical skincare that supports the skin in an oestrogen-deficient state should focus on barrier repair, collagen stimulation (retinoids remain relevant), and deep hydration support. Ceramide-containing moisturisers, hyaluronic acid serums, and niacinamide are rational choices. They will not restore what hormone withdrawal takes — but they support the skin in a depleted environment.
In clinic, treatments that stimulate new collagen — radiofrequency tightening, polynucleotide treatments, bio-remodelling injectables, laser modalities — have the most biological rationale for skin that has lost collagen through hormonal decline. Youth Preserve is an approach we use at SW1 that specifically addresses skin quality restoration at the dermal level.
But the honest clinical answer is: start with hormones. The treatments work better when the hormonal foundation is in place.
Skincare is maintenance. Hormones are infrastructure. You cannot adequately maintain infrastructure you don’t have.
References
[1] Hall, G., & Phillips, T. J. (2005). Estrogen and skin: The effects of estrogen, menopause, and hormone replacement therapy on the skin. Journal of the American Academy of Dermatology, 53(4), 555–568. https://doi.org/10.1016/j.jaad.2004.08.039 [VERIFY — confirm before publishing]
[2] Brincat, M. P. (2000). Hormone replacement therapy and the skin. Maturitas, 35(2), 107–117. https://doi.org/10.1016/S0378-5122(00)00097-9 [VERIFY — confirm before publishing]
[3] Khi, C., et al. (2014). Facial bone resorption in the ageing face: Patterns and implications for aesthetic treatment. Aesthetic Surgery Journal, 34(5), 687–694. [VERIFY — confirm before publishing]
